酪氨酸激酶抑制剂治疗软组织肉瘤的研究进展  

Research progress of tyrosine kinase inhibitor in the treatment of soft tissue sarcoma

作　　者：王寒 肖砚斌[1] 李文忠[1] 康建平 田昌平 朱昱衡 许昊俊 WANG Han;XIAO Yanbin;LI Wenzhong;KANG Jianping;TIAN Changping;ZHU Yuheng;XU Haojun(Department of 2nd Orthopedics,Yunnan Cancer Hospital,Yunnan Kunming 650118,China)

机构地区：[1]云南省肿瘤医院骨外二科,云南昆明650118

出　　处：《现代肿瘤医学》2024年第22期4396-4400,共5页Journal of Modern Oncology

基　　金：云南省科技厅-云南大学“双一流”联合基金项目(编号:2019FY003031)。

摘　　要：手术治疗是软组织肉瘤(soft tissue sarcomas,STS)的首选治疗方法,但预后尚不理想。目前,尽管使用包括手术、化疗、放疗在内的多种治疗方式,肿瘤的复发和转移仍然是软组织肉瘤患者预后和生存的难题。近年来,靶向治疗的兴起,尤其以酪氨酸激酶抑制剂(tyrosine kinase inhibitor,TKI)为代表的靶向药物让晚期无法手术或不能耐受化疗的软组织肉瘤患者获得了更好的生存。该文就国内外关于酪氨酸激酶抑制剂在软组织肉瘤中的研究进行综述。Surgical treatment is the preferred treatment for soft tissue sarcoma(STS),but the prognosis is not yet ideal.At present,despite the use of various treatment methods including surgery,chemotherapy,and radiation therapy,tumor recurrence and metastasis remain challenges for the prognosis and survival of patients with soft tissue sarcoma.In recent years,the rise of targeted therapy,especially targeted drugs represented by tyrosine kinase inhibitor(TKI),has enabled patients with advanced soft tissue sarcoma who cannot be operated or tolerate chemotherapy to achieve better survival.This article reviews domestic and international studies on tyrosine kinase inhibitors in soft tissue sarcoma.

关 键 词：软组织肉瘤 酪氨酸激酶抑制剂 靶向治疗 

分 类 号：R730.5[医药卫生—肿瘤]